Preclinical development of MGO Manuka Honey microemulsion for blepharitis management
ObjectiveTo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).Methods and analysis...
Saved in:
Published in | BMJ open ophthalmology Vol. 1; no. 1; p. e000065 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BMJ Publishing Group LTD
01.08.2017
BMJ Open Ophthalmology |
Subjects | |
Online Access | Get full text |
ISSN | 2397-3269 2397-3269 |
DOI | 10.1136/bmjophth-2016-000065 |
Cover
Loading…
Abstract | ObjectiveTo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).Methods and analysis In vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined. In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation.Results In vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa. In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05).ConclusionOverall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects. |
---|---|
AbstractList | ObjectiveTo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).Methods and analysisIn vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined.In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation.ResultsIn vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa.In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05).ConclusionOverall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects. To evaluate the antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME). phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for , and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for and with cyclodextrin-complexed and uncomplexed Manuka honey were determined. phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation. phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both and , but not . phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05). Overall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects. To evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).OBJECTIVETo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).In vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined. In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation.METHODS AND ANALYSISIn vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined. In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation.In vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa. In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05).RESULTSIn vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa. In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05).Overall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects.CONCLUSIONOverall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects. ObjectiveTo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).Methods and analysis In vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined. In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation.Results In vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa. In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05).ConclusionOverall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects. |
Author | Uy, Benedict Cheung, Isabella M Y Rupenthal, Ilva D Craig, Jennifer P Watters, Grant A Swift, Simon Seyfoddin, Ali Wang, Michael T M |
AuthorAffiliation | 1 Department of Ophthalmology , New Zealand National Eye Centre, The University of Auckland , Auckland , New Zealand 2 Faculty of Health and Environmental Sciences , School of Science, AUT University , Auckland , New Zealand 3 Department of Molecular Medicine and Pathology , The University of Auckland , Auckland , New Zealand |
AuthorAffiliation_xml | – name: 3 Department of Molecular Medicine and Pathology , The University of Auckland , Auckland , New Zealand – name: 1 Department of Ophthalmology , New Zealand National Eye Centre, The University of Auckland , Auckland , New Zealand – name: 2 Faculty of Health and Environmental Sciences , School of Science, AUT University , Auckland , New Zealand |
Author_xml | – sequence: 1 givenname: Jennifer P surname: Craig fullname: Craig, Jennifer P email: jp.craig@auckland.ac.nz organization: Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand – sequence: 2 givenname: Ilva D surname: Rupenthal fullname: Rupenthal, Ilva D email: jp.craig@auckland.ac.nz organization: Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand – sequence: 3 givenname: Ali surname: Seyfoddin fullname: Seyfoddin, Ali email: jp.craig@auckland.ac.nz organization: Faculty of Health and Environmental Sciences, School of Science, AUT University, Auckland, New Zealand – sequence: 4 givenname: Isabella M Y surname: Cheung fullname: Cheung, Isabella M Y email: jp.craig@auckland.ac.nz organization: Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand – sequence: 5 givenname: Benedict surname: Uy fullname: Uy, Benedict email: jp.craig@auckland.ac.nz organization: Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand – sequence: 6 givenname: Michael T M surname: Wang fullname: Wang, Michael T M email: jp.craig@auckland.ac.nz organization: Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand – sequence: 7 givenname: Grant A surname: Watters fullname: Watters, Grant A email: jp.craig@auckland.ac.nz organization: Department of Ophthalmology, New Zealand National Eye Centre, The University of Auckland, Auckland, New Zealand – sequence: 8 givenname: Simon surname: Swift fullname: Swift, Simon email: jp.craig@auckland.ac.nz organization: Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29354709$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU9LHTEUxUOxVKt-g1IC3XQzdTKZJJMuCiKtCoou7Drkry-vmWSazAh---bxfMW6sdkkcH_n3Jt73oO9mKIF4ANqvyCE6Yka12lazaumaxFt2nooeQMOOsxZgzvK956998FxKeuKII5o39F3YL_jmPSs5Qfg7jZbHXz0WgZo7IMNaRptnGFy8Pr8Bl7LuPyS8KK2f4Sj1znZcQnFpwhdylAFO61k9rMvcJRR3tuN-Ai8dTIUe_x0H4KfP77fnV00Vzfnl2enV43qGZ0bhAhv9eCw6ZwxcqCGSoaR7RXWg3FY6V5xx5Cmuh2kUUQ6ZChTVClJJFP4EHzb-k6LGq3RtXWWQUzZjzI_iiS9-LcS_UrcpwdBWIcoxtXg85NBTr8XW2Yx-qJtCDLatBSB-MA5IgT1Ff30Al2nJcf6PdFVgBFKUFupj88n-jvKbuEV-LoF6iZLydYJ7Wc5133WAX0QqBWbgMUuYLEJWGwDruL-hXjn_4rsZCur1f9T_AFAVL2N |
CitedBy_id | crossref_primary_10_1007_s00717_021_00497_3 crossref_primary_10_1136_bjophthalmol_2019_315160 crossref_primary_10_2147_OPTH_S440199 crossref_primary_10_1016_j_jtos_2017_05_006 crossref_primary_10_1515_biol_2025_1069 crossref_primary_10_3390_ph15111419 crossref_primary_10_3390_medicina60091458 crossref_primary_10_1016_j_jtos_2019_02_010 crossref_primary_10_3390_pharmaceutics14071493 crossref_primary_10_1016_j_clae_2018_06_006 crossref_primary_10_1016_j_jtos_2019_11_009 crossref_primary_10_1089_jop_2019_0135 |
Cites_doi | 10.1097/OPX.0000000000000601 10.1097/01.ico.0000225716.85382.7b 10.1167/iovs.10-6997g 10.1093/jac/dkr340 10.1111/j.1444-0938.2001.tb04930.x 10.1111/j.1444-0938.2010.00540.x 10.1016/j.carres.2007.12.011 10.1097/01.ICL.0000095229.01957.89 10.1016/j.jtos.2016.03.002 10.1097/ICL.0000000000000124 10.1016/S1542-0124(12)70620-1 10.1096/fj.09-150789 10.1007/s10973-011-1406-z 10.1016/j.tim.2004.11.001 10.1007/s10096-010-1121-x 10.1097/ICO.0b013e3181bd4756 10.1167/iovs.10-6997a 10.1080/01676830600666185 10.1097/00003226-200310000-00008 10.1016/S1773-2247(11)50078-4 10.1615/CritRevTherDrugCarrierSyst.v14.i1.10 10.1097/00003226-199110010-00010 10.1136/bjo.68.8.524 10.1111/j.2042-7158.1991.tb03186.x 10.1016/j.jtos.2014.05.005 10.1016/S0308-8146(03)00258-9 10.1002/jps.23077 10.31989/ffhd.v4i5.13 10.1007/978-1-4615-5359-5_141 10.1016/S0580-9517(08)70474-4 10.1111/ceo.12810 10.1007/BF00656817 10.1167/iovs.12-9922 10.1007/978-1-4615-5359-5_121 |
ContentType | Journal Article |
Copyright | Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2016 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2016 |
Copyright_xml | – notice: Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted. – notice: 2016 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2016. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2016 |
DBID | 9YT ACMMV AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1136/bmjophth-2016-000065 |
DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest One Academic Eastern Edition PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2397-3269 |
ExternalDocumentID | PMC5721633 29354709 10_1136_bmjophth_2016_000065 bmjophth |
Genre | Journal Article |
GeographicLocations | New Zealand United States--US |
GeographicLocations_xml | – name: United States--US – name: New Zealand |
GrantInformation_xml | – fundername: ; |
GroupedDBID | 53G 5VS 7X7 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BCNDV BENPR BTFSW CCPQU FYUFA GROUPED_DOAJ H13 HMCUK HYE M~E O9- OK1 RHI RMJ RPM UKHRP AAYXX CITATION NPM RHF 3V. 7XB 8FK K9. PQEST PQQKQ PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-b476t-11590c8f3d2fdda86d6a731e4b3c8df3bc4b9f71c6c08adb5af1d67b6bba5a7b3 |
IEDL.DBID | 9YT |
ISSN | 2397-3269 |
IngestDate | Thu Aug 21 14:13:05 EDT 2025 Fri Jul 11 16:15:34 EDT 2025 Mon Jun 30 04:12:03 EDT 2025 Thu Jan 02 22:55:07 EST 2025 Wed Sep 03 16:44:52 EDT 2025 Thu Apr 24 23:03:07 EDT 2025 Thu Apr 24 23:05:54 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | methylglyoxal Blepharitis Manuka honey cyclodextrin |
Language | English |
License | This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b476t-11590c8f3d2fdda86d6a731e4b3c8df3bc4b9f71c6c08adb5af1d67b6bba5a7b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://dx.doi.org/10.1136/bmjophth-2016-000065 |
PMID | 29354709 |
PQID | 2551756510 |
PQPubID | 5161127 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5721633 proquest_miscellaneous_1989915514 proquest_journals_2551756510 pubmed_primary_29354709 crossref_citationtrail_10_1136_bmjophth_2016_000065 crossref_primary_10_1136_bmjophth_2016_000065 bmj_primary_10_1136_bmjophth_2016_000065 |
PublicationCentury | 2000 |
PublicationDate | 2017-08-01 |
PublicationDateYYYYMMDD | 2017-08-01 |
PublicationDate_xml | – month: 08 year: 2017 text: 2017-08-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
PublicationTitle | BMJ open ophthalmology |
PublicationTitleAlternate | BMJ Open Ophthalmol |
PublicationYear | 2017 |
Publisher | BMJ Publishing Group LTD BMJ Open Ophthalmology |
Publisher_xml | – name: BMJ Publishing Group LTD – name: BMJ Open Ophthalmology |
References | Dougherty, McCulley 1986; 27 Thompson 1997; 14 Swift, Chepulis, Uy 2014; 4 Jenkins, Burton, Cooper 2011; 66 Fux, Shirtliff, Stoodley 2005; 13 Albietz 2001; 84 Geerling, Tauber, Baudouin 2011; 52 Wang, Jaitley, Lord 2015; 92 MacKeen, Roth, Doane 1998; 438 Habib, El-Mahdy, Maher 2011; 21 Lemp, Nichols 2009; 7 Guillon 1998; 438 Romero, Biser, Perry 2004; 30 Mukherjee, Chaki, Das 2011; 49 Adams, Boult, Deadman 2008; 343 Dougherty, McCulley 1984; 68 Groden, Murphy, Rodnite 1991; 10 Snow, Manley-Harris 2004; 84 Bron, Evans, Smith 2003; 22 Albietz, Lenton 2006; 25 Nichols, Foulks, Bron 2011; 52 Allen, Molan, Reid 1991; 43 Chadha, Arora, Gupta 2011; 105 Hughes, Ahmed, Hammond 2007; 26 Goto, Zheng, Gibbon 2010; 29 Á, Szejtli, Barcza 1983; 1 Lee, DH, Jung 2012; 53 Opitz, Tyler 2011; 94 Pflugfelder, Karpecki, Perez 2014; 12 Lindsley, Matsumura, Hatef 2012; 5 Loftsson, Brewster 2012; 101 Lin, Molan, Cursons 2011; 30 Watters, Turnbull, Swift 2017; 45 Schleifer, Kandler 1972; 36 Ng, Evans, North 2015; 41 Craig, Wang, Kim 2016; 14 Kwakman, te Velde, de Boer 2010; 24 2025090109161508000_1.1.e000065.5 2025090109161508000_1.1.e000065.4 Craig (2025090109161508000_1.1.e000065.23) 2016; 14 Pflugfelder (2025090109161508000_1.1.e000065.9) 2014; 12 2025090109161508000_1.1.e000065.3 2025090109161508000_1.1.e000065.2 Watters (2025090109161508000_1.1.e000065.6) 2017; 45 Guillon (2025090109161508000_1.1.e000065.22) 1998; 438 Albietz (2025090109161508000_1.1.e000065.13) 2001; 84 Habib (2025090109161508000_1.1.e000065.32) 2011; 21 Chadha (2025090109161508000_1.1.e000065.34) 2011; 105 2025090109161508000_1.1.e000065.21 Mukherjee (2025090109161508000_1.1.e000065.29) 2011; 49 Swift (2025090109161508000_1.1.e000065.20) 2014; 4 Thompson (2025090109161508000_1.1.e000065.19) 1997; 14 Dougherty (2025090109161508000_1.1.e000065.10) 1986; 27 2025090109161508000_1.1.e000065.28 2025090109161508000_1.1.e000065.27 2025090109161508000_1.1.e000065.26 2025090109161508000_1.1.e000065.25 2025090109161508000_1.1.e000065.24 Ng (2025090109161508000_1.1.e000065.35) 2015; 41 Goto (2025090109161508000_1.1.e000065.37) 2010; 29 Lindsley (2025090109161508000_1.1.e000065.1) 2012; 5 MacKeen (2025090109161508000_1.1.e000065.36) 1998; 438 Lin (2025090109161508000_1.1.e000065.30) 2011; 30 Groden (2025090109161508000_1.1.e000065.8) 1991; 10 2025090109161508000_1.1.e000065.31 Hughes (2025090109161508000_1.1.e000065.7) 2007; 26 Á (2025090109161508000_1.1.e000065.33) 1983; 1 2025090109161508000_1.1.e000065.18 2025090109161508000_1.1.e000065.17 Wang (2025090109161508000_1.1.e000065.15) 2015; 92 2025090109161508000_1.1.e000065.16 2025090109161508000_1.1.e000065.14 2025090109161508000_1.1.e000065.12 2025090109161508000_1.1.e000065.11 |
References_xml | – volume: 92 start-page: e321 year: 2015 article-title: Comparison of Self-applied Heat Therapy for Meibomian Gland Dysfunction publication-title: Optom Vis Sci doi: 10.1097/OPX.0000000000000601 – volume: 25 start-page: 1012 year: 2006 article-title: Effect of antibacterial honey on the ocular flora in tear deficiency and meibomian gland disease publication-title: Cornea doi: 10.1097/01.ico.0000225716.85382.7b – volume: 52 start-page: 2050 year: 2011 article-title: The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-6997g – volume: 66 start-page: 2536 year: 2011 article-title: Manuka honey inhibits cell division in methicillin-resistant Staphylococcus aureus publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr340 – volume: 84 start-page: 4 year: 2001 article-title: Dry eye: an update on clinical diagnosis, management and promising new treatments publication-title: Clin Exp Optom doi: 10.1111/j.1444-0938.2001.tb04930.x – volume: 94 start-page: 200 year: 2011 article-title: Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis publication-title: Clin Exp Optom doi: 10.1111/j.1444-0938.2010.00540.x – volume: 36 start-page: 407 year: 1972 article-title: Peptidoglycan types of bacterial cell walls and their taxonomic implications publication-title: Bacteriol Rev – volume: 343 start-page: 651 year: 2008 article-title: Isolation by HPLC and characterisation of the bioactive fraction of New Zealand manuka (Leptospermum scoparium) honey publication-title: Carbohydr Res doi: 10.1016/j.carres.2007.12.011 – volume: 53 start-page: 5585 year: 2012 article-title: Comparative Ocular Microbial Communities in Humans with and without BlepharitisOcular Microbial Communities publication-title: Investigative ophthalmology & visual science – volume: 30 start-page: 14 year: 2004 article-title: Conservative treatment of meibomian gland dysfunction publication-title: Eye Contact Lens doi: 10.1097/01.ICL.0000095229.01957.89 – volume: 14 start-page: 385 year: 2016 article-title: Exploring the Predisposition of the Asian Eye to Development of Dry Eye publication-title: Ocul Surf doi: 10.1016/j.jtos.2016.03.002 – volume: 41 start-page: 304 year: 2015 article-title: Migration of Cosmetic Products into the Tear Film publication-title: Eye Contact Lens doi: 10.1097/ICL.0000000000000124 – volume: 7 start-page: S1 year: 2009 article-title: Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment publication-title: Ocul Surf doi: 10.1016/S1542-0124(12)70620-1 – volume: 24 start-page: 2576 year: 2010 article-title: How honey kills bacteria publication-title: FASEB J doi: 10.1096/fj.09-150789 – volume: 105 start-page: 1049 year: 2011 article-title: Complexation of nevirapine with β-cyclodextrins in the presence and absence of Tween 80: characterization, thermodynamic parameters, and permeability flux publication-title: J Therm Anal Calorim doi: 10.1007/s10973-011-1406-z – volume: 27 start-page: 486 year: 1986 article-title: Bacterial lipases and chronic blepharitis publication-title: Invest Ophthalmol Vis Sci – volume: 45 start-page: 105 year: 2017 article-title: Ocular surface microbiome in meibomian gland dysfunction in Auckland, New Zealand publication-title: Clin Exp Ophthalmol – volume: 4 start-page: 172 year: 2014 article-title: Enhanced Antibacterial Activity of MGOTM Manuka Honey complexed with a-cyclodextrin (Manuka Honey with CycloPowerTM) publication-title: Functional Foods in Health and Disease – volume: 13 start-page: 58 year: 2005 article-title: Can laboratory reference strains mirror "real-world" pathogenesis? publication-title: Trends Microbiol doi: 10.1016/j.tim.2004.11.001 – volume: 30 start-page: 569 year: 2011 article-title: The controlled in vitro susceptibility of gastrointestinal pathogens to the antibacterial effect of manuka honey publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-010-1121-x – volume: 1 start-page: 151 year: 1983 article-title: Complexes of short-chain alcohols with β-cyclodextrin publication-title: Journal of inclusion phenomena – volume: 438 start-page: 859 year: 1998 article-title: Use of the Tearscope Plus and attachments in the routine examination of the marginal dry eye contact lens patient publication-title: Adv Exp Med Biol – volume: 29 start-page: 400 year: 2010 article-title: Cosmetic product migration onto the ocular surface: exacerbation of migration after eyedrop instillation publication-title: Cornea doi: 10.1097/ICO.0b013e3181bd4756 – volume: 52 start-page: 1922 year: 2011 article-title: The international workshop on meibomian gland dysfunction: executive summary publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.10-6997a – volume: 26 start-page: 47 year: 2007 article-title: Necrotizing pseudomonas blepharoconjunctivitis publication-title: Orbit doi: 10.1080/01676830600666185 – volume: 22 start-page: 640 year: 2003 article-title: Grading of corneal and conjunctival staining in the context of other dry eye tests publication-title: Cornea doi: 10.1097/00003226-200310000-00008 – volume: 21 start-page: 485 year: 2011 article-title: Microemulsions for ocular delivery: evaluation and characterization publication-title: J Drug Deliv Sci Technol doi: 10.1016/S1773-2247(11)50078-4 – volume: 14 start-page: 1 year: 1997 article-title: Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals publication-title: Crit Rev Ther Drug Carrier Syst doi: 10.1615/CritRevTherDrugCarrierSyst.v14.i1.10 – volume: 5 year: 2012 article-title: Interventions for chronic blepharitis publication-title: Cochrane Database Syst Rev – volume: 10 start-page: 50 year: 1991 article-title: Lid flora in blepharitis publication-title: Cornea doi: 10.1097/00003226-199110010-00010 – volume: 68 start-page: 524 year: 1984 article-title: Comparative bacteriology of chronic blepharitis publication-title: Br J Ophthalmol doi: 10.1136/bjo.68.8.524 – volume: 43 start-page: 817 year: 1991 article-title: A survey of the antibacterial activity of some New Zealand honeys publication-title: J Pharm Pharmacol doi: 10.1111/j.2042-7158.1991.tb03186.x – volume: 49 start-page: 547 year: 2011 article-title: Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa publication-title: Indian J Exp Biol – volume: 438 start-page: 985 year: 1998 article-title: Supracutaneous treatment of dry eye patients with calcium carbonate publication-title: Adv Exp Med Biol – volume: 12 start-page: 273 year: 2014 article-title: Treatment of blepharitis: recent clinical trials publication-title: Ocul Surf doi: 10.1016/j.jtos.2014.05.005 – volume: 84 start-page: 145 year: 2004 article-title: On the nature of non-peroxide antibacterial activity in New Zealand manuka honey publication-title: Food Chem doi: 10.1016/S0308-8146(03)00258-9 – volume: 101 start-page: 3019 year: 2012 article-title: Cyclodextrins as functional excipients: methods to enhance complexation efficiency publication-title: J Pharm Sci doi: 10.1002/jps.23077 – volume: 4 start-page: 172 year: 2014 ident: 2025090109161508000_1.1.e000065.20 article-title: Enhanced Antibacterial Activity of MGOTM Manuka Honey complexed with a-cyclodextrin (Manuka Honey with CycloPowerTM) publication-title: Functional Foods in Health and Disease doi: 10.31989/ffhd.v4i5.13 – ident: 2025090109161508000_1.1.e000065.25 doi: 10.1016/j.carres.2007.12.011 – volume: 12 start-page: 273 year: 2014 ident: 2025090109161508000_1.1.e000065.9 article-title: Treatment of blepharitis: recent clinical trials publication-title: Ocul Surf doi: 10.1016/j.jtos.2014.05.005 – ident: 2025090109161508000_1.1.e000065.14 doi: 10.1097/01.ICL.0000095229.01957.89 – volume: 84 start-page: 4 year: 2001 ident: 2025090109161508000_1.1.e000065.13 article-title: Dry eye: an update on clinical diagnosis, management and promising new treatments publication-title: Clin Exp Optom doi: 10.1111/j.1444-0938.2001.tb04930.x – ident: 2025090109161508000_1.1.e000065.28 doi: 10.1096/fj.09-150789 – ident: 2025090109161508000_1.1.e000065.12 doi: 10.1111/j.1444-0938.2010.00540.x – ident: 2025090109161508000_1.1.e000065.24 doi: 10.1097/00003226-200310000-00008 – ident: 2025090109161508000_1.1.e000065.5 doi: 10.1136/bjo.68.8.524 – volume: 105 start-page: 1049 year: 2011 ident: 2025090109161508000_1.1.e000065.34 article-title: Complexation of nevirapine with β-cyclodextrins in the presence and absence of Tween 80: characterization, thermodynamic parameters, and permeability flux publication-title: J Therm Anal Calorim doi: 10.1007/s10973-011-1406-z – volume: 438 start-page: 985 year: 1998 ident: 2025090109161508000_1.1.e000065.36 article-title: Supracutaneous treatment of dry eye patients with calcium carbonate publication-title: Adv Exp Med Biol doi: 10.1007/978-1-4615-5359-5_141 – volume: 14 start-page: 1 year: 1997 ident: 2025090109161508000_1.1.e000065.19 article-title: Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals publication-title: Crit Rev Ther Drug Carrier Syst doi: 10.1615/CritRevTherDrugCarrierSyst.v14.i1.10 – volume: 26 start-page: 47 year: 2007 ident: 2025090109161508000_1.1.e000065.7 article-title: Necrotizing pseudomonas blepharoconjunctivitis publication-title: Orbit doi: 10.1080/01676830600666185 – volume: 49 start-page: 547 year: 2011 ident: 2025090109161508000_1.1.e000065.29 article-title: Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa publication-title: Indian J Exp Biol – volume: 21 start-page: 485 year: 2011 ident: 2025090109161508000_1.1.e000065.32 article-title: Microemulsions for ocular delivery: evaluation and characterization publication-title: J Drug Deliv Sci Technol doi: 10.1016/S1773-2247(11)50078-4 – volume: 14 start-page: 385 year: 2016 ident: 2025090109161508000_1.1.e000065.23 article-title: Exploring the Predisposition of the Asian Eye to Development of Dry Eye publication-title: Ocul Surf doi: 10.1016/j.jtos.2016.03.002 – ident: 2025090109161508000_1.1.e000065.21 doi: 10.1111/j.2042-7158.1991.tb03186.x – ident: 2025090109161508000_1.1.e000065.31 doi: 10.1016/j.tim.2004.11.001 – ident: 2025090109161508000_1.1.e000065.26 doi: 10.1093/jac/dkr340 – volume: 27 start-page: 486 year: 1986 ident: 2025090109161508000_1.1.e000065.10 article-title: Bacterial lipases and chronic blepharitis publication-title: Invest Ophthalmol Vis Sci – ident: 2025090109161508000_1.1.e000065.3 doi: 10.1167/iovs.10-6997a – ident: 2025090109161508000_1.1.e000065.11 doi: 10.1167/iovs.10-6997g – ident: 2025090109161508000_1.1.e000065.18 doi: 10.1002/jps.23077 – volume: 92 start-page: e321 year: 2015 ident: 2025090109161508000_1.1.e000065.15 article-title: Comparison of Self-applied Heat Therapy for Meibomian Gland Dysfunction publication-title: Optom Vis Sci doi: 10.1097/OPX.0000000000000601 – volume: 30 start-page: 569 year: 2011 ident: 2025090109161508000_1.1.e000065.30 article-title: The controlled in vitro susceptibility of gastrointestinal pathogens to the antibacterial effect of manuka honey publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-010-1121-x – ident: 2025090109161508000_1.1.e000065.27 doi: 10.1016/S0580-9517(08)70474-4 – volume: 29 start-page: 400 year: 2010 ident: 2025090109161508000_1.1.e000065.37 article-title: Cosmetic product migration onto the ocular surface: exacerbation of migration after eyedrop instillation publication-title: Cornea doi: 10.1097/ICO.0b013e3181bd4756 – ident: 2025090109161508000_1.1.e000065.17 doi: 10.1016/S0308-8146(03)00258-9 – volume: 5 year: 2012 ident: 2025090109161508000_1.1.e000065.1 article-title: Interventions for chronic blepharitis publication-title: Cochrane Database Syst Rev – ident: 2025090109161508000_1.1.e000065.2 doi: 10.1016/S1542-0124(12)70620-1 – volume: 10 start-page: 50 year: 1991 ident: 2025090109161508000_1.1.e000065.8 article-title: Lid flora in blepharitis publication-title: Cornea doi: 10.1097/00003226-199110010-00010 – volume: 41 start-page: 304 year: 2015 ident: 2025090109161508000_1.1.e000065.35 article-title: Migration of Cosmetic Products into the Tear Film publication-title: Eye Contact Lens doi: 10.1097/ICL.0000000000000124 – volume: 45 start-page: 105 year: 2017 ident: 2025090109161508000_1.1.e000065.6 article-title: Ocular surface microbiome in meibomian gland dysfunction in Auckland, New Zealand publication-title: Clin Exp Ophthalmol doi: 10.1111/ceo.12810 – ident: 2025090109161508000_1.1.e000065.16 doi: 10.1097/01.ico.0000225716.85382.7b – volume: 1 start-page: 151 year: 1983 ident: 2025090109161508000_1.1.e000065.33 article-title: Complexes of short-chain alcohols with β-cyclodextrin publication-title: Journal of inclusion phenomena doi: 10.1007/BF00656817 – ident: 2025090109161508000_1.1.e000065.4 doi: 10.1167/iovs.12-9922 – volume: 438 start-page: 859 year: 1998 ident: 2025090109161508000_1.1.e000065.22 article-title: Use of the Tearscope Plus and attachments in the routine examination of the marginal dry eye contact lens patient publication-title: Adv Exp Med Biol doi: 10.1007/978-1-4615-5359-5_121 |
SSID | ssj0001916426 |
Score | 2.0821202 |
Snippet | ObjectiveTo evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with... To evaluate the antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and rabbit eye... To evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in... |
SourceID | pubmedcentral proquest pubmed crossref bmj |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | e000065 |
SubjectTerms | Antibiotics Bacteria Drug resistance Honey Inflammation Laboratories Microemulsions Original |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELbGkBAvCNiAwEBG4mEv0erYsZMnhNBGhdTBwyb1zfKvqLA2KbR94L_nznHTdUjAaxzL1vl89_n8-Y6Qd8wrCyjcgfWrRC4qC3ZQcpl7Xklw-CGomPFmcinH1-LztJymgNsq0Sq3NjEaat85jJGfAfQFTydBhd4vf-RYNQpvV1MJjXvkPqYuQ0qXmqpdjAWwjyj6-nI17KVC1un1HOPyzC6-d8vZegaKwmQeDTd6GPi876P-AJ53-ZO3HNLFY_IoIUn6oV_6J-QgtE_Jg0m6Kz8iV1_BmKV3j9TvuEG0a-jk0xc6Me3mxtBx14ZfdIG8vLDYzDF4RgHIUjsPy5mJKY_oYuDIHJPri_Orj-M81VDIrVBynQPgq0euargvGu9NJb00irMgLHeVb7h1wtaNYk66UWW8LU3DvFRWWmtKoyx_Rg5bmMgLQn3NDR5_rKiNKFhT4Q_MAz4IjWDBZeQUZKeXfZYMHU8XXOqtmDWKWfdizgjfCli7lIscS2LM_9ErH3r93ygn27XTaWeu9E6PMvJ2aIY9hRclpg3dZqWRR1ZHLJmR5_1SDwMCPCqFGtUZUXtKMPyA-br3W9pvs5i3u8RESZy__Pu0XpGHBUKHSDI8IYfrn5vwGoDP2r6J2v0bGrYB3Q priority: 102 providerName: ProQuest |
Title | Preclinical development of MGO Manuka Honey microemulsion for blepharitis management |
URI | http://bmjophth.bmj.com/content/1/1/e000065.full https://www.ncbi.nlm.nih.gov/pubmed/29354709 https://www.proquest.com/docview/2551756510 https://www.proquest.com/docview/1989915514 https://pubmed.ncbi.nlm.nih.gov/PMC5721633 |
Volume | 1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dT9swED8NkNBeEGxshI_Kk_awl2h17djJIyCgmhSGpoLKk2XHjrrRphW0D_z3nN00pSA0niL5Q47u7Lvf2eefAb5TKw2i8AKtX8pjnhq0g4KJ2LJUoMN3TgbGm_xSdK_5r37SXwaKL07wKRM_zejfeDKYDlCfVMTBviZrsBFoWfyMvu0t91QQ66DHqW_IvdUZvQgWr_qhV-DyZY7kM6dzvg1bNVokx3P17sAHV32Czbw-D_8MvSs0WPXdRmKX-T9kXJL84jfJdTW706Q7rtwjGfncOzeaDf0GGUGwSszQTQY60BqRUZMHswvX52e9025cv5MQGy7FNEZQl7WLtGS2U1qrU2GFlow6bliR2pKZgpuslLQQRTvV1iS6pFZII4zRiZaGfYH1Cn9kD4jNmPYhjuGZ5h1apr4BtYgBXMmpKyL4gbJTkzkThgoRBBNqIWblxazmYo6ALQSsippv3D97MfxPr7jp9b5RDhe6U_Xqe1AYJiEqEmhuIvjWVOO68YchunLj2YPyuWJZwIsRfJ2ruhkQIVDCZTuLQK5MgqaB5-Reran-DgI3d-LJkBjbf7-cDuBjx0OFkFR4COvT-5k7QqAzNS1Yk33ZCnO8BRvHp3l-g9-Ts8urP62wefAEW6H_tg |
linkProvider | BMJ Publishing Group Ltd |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJe0PgODDASSLxEq2PHSR7QxMdGx5YyoU7am2fHjgq0SaGtpv1T-xs556sUJOBlr7EdW-fz3e_O5zuAF9REGlF4htIv5j6PNcpBwYRvWCxQ4VsbVRlv0qEYnPCPp-HpBly2b2FcWGUrEytBbcrM-ch3EPqiphPIQruz776rGuVuV9sSGjVbHNqLczTZ5q8P3uP-vgyC_b3Ru4HfVBXwNY_EwkcIlPSzOGcmyI1RsTBCRYxarlkWm5zpjOskj2gmsn6sjA5VTo2ItNBahSrSDP97DTY5Q1OmB5tv94bHn1deHURbPKgr2iV4egORNO_1KBM7evq1nI0XY2RNKvxKVTidhp_XteIfUPf3iM1fVOD-FtxqsCt5UzPbbdiwxR24nja383dhdIzis3lpScwqGomUOUk_fCKpKpbfFBmUhb0gUxcJaKfLiXPXEYTORE_sbKyqJEtk2kXl3IOTK6HvfegVuJCHQEzClDO4NE8UD2geuw7UICKxOac28-AV0k7O6rwcsrJnmJAtmaUjs6zJ7AFrCSyzJvu5K8Ix-ccovxv1f7Nst3snG1kwlyvO9eB514yn2F3NqMKWy7l0kWtJhV49eFBvdTchArKQR_3Eg2iNCboOLkP4ekvxZVxlCg9daibGHv19Wc_gxmCUHsmjg-HhY7gZOOBShThuQ2_xY2mfIOxa6KcNrxM4u-rj9RNYv0LU |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4aQ5p4QdwXtoGRQOIlah07dvKA0MQoHaNjD5vUN2PHjgq0SVlbof01fh3HuZWCBLzsNY7j6PhcPtufzwF4Tq00iMIz9H4JD3li0A8KJkLLEoEB3zlZZbwZnYrhBX8_jsdb8KO9C-Npla1PrBy1LTO_R95D6IuRTqAK9fKGFnF2NHg9_xb6ClL-pLUtp1GryIm7-o7Lt8Wr4yOc6xdRNHh7_mYYNhUGQsOlWIYIh9J-luTMRrm1OhFWaMmo44Zlic2ZybhJc0kzkfUTbU2sc2qFNMIYHWtpGH73BtyULKbexuRYrvd3EHfxqK5tl6IdRyJtbu5RJnpm9qWcT5YTVFIqwipo-OiGjzfj4x-g93fu5i_BcHAHbjcolhzWancXtlxxD3ZGzTn9fTg_Q0fa3Lkkds1LImVORu8-kpEuVl81GZaFuyIzzwl0s9XUb9wRBNHETN18oqt0S2TW8XMewMW1SPchbBf4I7tAbMq0X3oZnmoe0TzxL1CL2MTlnLosgJcoOzWvM3SoamXDhGrFrLyYVS3mAFgrYJU1edB9OY7pP3qFXa__G2W_nTvVeIWFWutwAM-6ZrRnf0ijC1euFspz2NIKxwbwqJ7qbkCEZjGX_TQAuaEE3Qs-V_hmS_F5UuUMj32SJsYe__23nsIOGpX6cHx6sge3Io9gKq7jPmwvL1fuAPHX0jypFJ3Ap-u2rJ-koUWk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preclinical+development+of+MGO+Manuka+Honey+microemulsion+for+blepharitis+management&rft.jtitle=BMJ+open+ophthalmology&rft.au=Craig%2C+Jennifer+P&rft.au=Rupenthal%2C+Ilva+D&rft.au=Seyfoddin%2C+Ali&rft.au=Cheung%2C+Isabella+M+Y&rft.date=2017-08-01&rft.eissn=2397-3269&rft.volume=1&rft.issue=1&rft_id=info:doi/10.1136%2Fbmjophth-2016-000065&rft.externalDBID=bmjophth&rft.externalDocID=bmjophth |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2397-3269&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2397-3269&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2397-3269&client=summon |